In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk. Oliver D, Talley NJ. Ann Intern Med 2022 Oct 4. doi: 10.7326/J22-0080.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Oliver D, Talley NJ. In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk. Ann Intern Med 2022 Oct 4. doi: 10.7326/J22-0080.
PMID: 36191314